Advertisement

Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80
Document › Details

SolasCure Ltd.. (8/9/21). "Press Release: SolasCure Announces £15m Series A Raise".

Organisations Organisation SolasCure Ltd.
  Organisation 2 BRAIN Biotech AG
  Group BRAIN Biotech (Group)
Products Product Aurase® wound cleaning product
  Product 2 venture capital
Index terms Index term SolasCure–SEVERAL: investment, 201808–202108 financing round Series A £15m led by Brain Biotech AG
  Index term 2 SolasCure–Seneca Partners: investment, 201808–202108 financing round Series A totalling £15m incl co-investor Seneca Partners
Persons Person Bakri, Sam (SolasCure 202108 CEO + Founder)
  Person 2 Moelker, Adriaan (BRAIN 202002– CEO before Flint Group + AB Enzymes + Genencor + DSM)
     


Biotech start-up SolasCure has announced the completion of its Series A investment round, to support the development of its wound cleaning product, Aurase®.

The Cambridge based biotech company has successfully completed its Series A raise of £15m, with funding from industry veterans, institutional venture and strategic investors.

SolasCure is developing proprietary technology leveraging biomimicry and evidence-based medicine to empower health care professionals to treat patients with chronic wounds. Their first investigational product, Aurase®, is a hydrogel containing an enzyme cloned from medical maggots that can be used to support healthcare professionals treating patients with chronic wounds.

Speaking upon the completion of the round, Dr Sam Bakri, Founder and CEO of SolasCure said: “We are delighted to have completed our Series A round, which will help us to move onto the clinical trial stages of product development. We are excited to be working with such knowledgeable and specialist investors, as they join us on our mission to support healthcare professionals with wound care products that significantly improve the health and wellbeing of patients with chronic wounds.”

The raise began with investment from BRAIN Biotech AG (Xetra:BNN), who are SolasCure’s largest shareholder.

Adriaan Moelker, CEO BRAIN Biotech AG, said: “It has been an encouraging sign for all partners that SolasCure has been able to successfully close another financing round with rising pre-money valuation during the pandemic. We continue to be committed to support SolasCure on its way to market for the innovative wound debridement enzyme Aurase®.

The round was completed following investment by Seneca Partners, an investment management business based in the UK.

Speaking on their investment, Matt Currie, Investment Director at Seneca said: “We are delighted to support SolasCure as part of this latest funding round. The team they have brought together are truly world-class, producing ground-breaking work in the wound care sector. Practitioners are crying out for a high-quality solution that can be transported, stored and administered in an efficient and effective way, something severely lacking in the treatments available at present. We believe SolasCure’s Aurase product has the potential to become the go-to solution in this space”.

In addition to the investments from BRAIN Biotech AG and Seneca Partners, other notable investors to date include Bionova Capital, experienced entrepreneur and life sciences angel investor Jonathan Milner (founder of Abcam), strategic investor EVA Pharma, the Development Bank of Wales, as well as François Fournier (former lead of Smith & Nephew’s Advanced Wound Care division). The GS Verde Group acted as advisors to the fundraise.

   
Record changed: 2021-08-26

Advertisement

Picture [iito] Made Without Love 650x80px

More documents for SolasCure Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Network in German Capital Region 650x80px




» top